Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases
نویسندگان
چکیده
Psoriasis is a chronic skin disease caused by the excessive secretion of inflammatory cytokines. Available therapeutic options include biologic drugs such as tumor necrosis factor alpha inhibitors and interleukin 12/23 (IL-12/23) inhibitors. The recent discovery of IL-17, which contributes to development of psoriasis, opened new possibilities for further treatment modalities. Currently, one anti-IL17 biological agent is approved for the treatment - a fully human monoclonal antibody that targets IL-17A (secukinumab). Further clinical trials, including a humanized IgG4 specific for IL-17 (ixekizumab) and a fully human antibody that targets the IL-17 receptor A (brodalumab).
منابع مشابه
Prevalence and risk factors of joint diseases in patients with Psoriasis referred to Razi Skin Hospital in Tehran
Background: Psoriatic arthropathy is a seronegative arthropathy seen in some patients with psoriasis, a self-limited and genetically determined skin disease. Objective: To determine the prevalence and risk factors of arthropathy in patients with psoriasis. Patients and Methods: In a prospective, cross-sectional study, psoriatic patients referred to Razi Skin Hospital in Tehran, Iran in 20...
متن کاملNew and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors
The development of effective and well-tolerated biologic therapies has advanced the management of psoriasis by enabling clinicians to treat underlying disease mechanisms. Biologics approved for the treatment of moderate-to-severe psoriasis include three tumor necrosis factor alpha inhibitors and an interleukin-12/interleukin-23 inhibitor. The establishment of the immunological basis of psoriasi...
متن کاملThe role of IL‐23 and the IL‐23/TH17 immune axis in the pathogenesis and treatment of psoriasis
Psoriasis is a chronic, immune-mediated disease affecting more than 100 million people worldwide and up to 2.2% of the UK population. The aetiology of psoriasis is thought to originate from an interplay of genetic, environmental, infectious and lifestyle factors. The manner in which genetic and environmental factors interact to contribute to the molecular disease mechanisms has remained elusive...
متن کاملSpotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy
Brodalumab is a novel fully human immunoglobulin G2 monoclonal antibody that antagonizes the interleukin (IL)-17 pathway by binding with high affinity to human IL-17RA. The role of IL-17A in the pathogenesis of psoriasis, as well as the remarkable effectiveness of IL-17 inhibitors in the treatment of moderate-to-severe plaque psoriasis, is well established. The mechanism of action of brodalumab...
متن کاملPrevalence of Candida in saliva and skin lesions of Psoriasis Vulgaris patients
Knowledge is of great importance; therefore it is very crucial to use an antifungal agent asadditional treatment for psoriasis in patients. This study was designed to evaluate thepresence of Candida albicans and other species of Candida in the saliva and skin of 50psoriatic patients. The result of this study was compared to the control group of 50healthy people. This research study was carried ...
متن کامل